Co-virion Rapid Antigen Test is an immunochromatographic test designed to qualitatively detect SARS-CoV- 2 antigen in nasopharyngeal geal swab specimens. It is intended to aid in the rapid diagnosis of SARS-CoV-2 infections.
Co-virion Rapid Antigen Test is an immunochromatographic test designed to detect the nucleocapsid protein of SARS-CoV-2 in nasopharyngeal swabs (NP). The test strip contains colloidal-gold conjugated particles with monoclonal antibodies against the nu- cleo- capsid protein of SARS-CoV-2. The capture antibodies for nucleocapsid protein of SARS-CoV-2 are coated on the nitrocellulose membrane. When the sample is applied to the sample window (S well), the conjugates dried in the reagent pad are dissolved and migrate along with the sample. If SARS-CoV-2 is present in the sample, a complex formed between the anti-SARS-CoV-2 conjugate and the virus will be captured by the specific an- ti-SARS-CoV-2 monoclonal antibodies coated on the test line region (T), which develops a red line in T region. Presence of T line indicates a positive result. There is also an internal control line to check the accuracy of the test performance. The control line is coated with goat anti-Rabbit IgG antibody which binds to the gold labeled antibody. Failure to form C line confirms the incorrect procedural technique.
Cov-inu RT-PCR kit is a probe based Real Time PCR test designed for the qualitative de- tection of SARS-CoV-2 Coronavirus, the etiological agent of COVID-2019 and A + B Group Inuenza virus (orthomyxovirus). It is used to detect S- M2 ve NS1 genes in viral RNA.
Description of the Kit
Cov-inu RT PCR Kit is a multiplex PCR kit that is used for the simultaneous detection of COVID-19 agent SARS-COV-2 and Inuenza A and Inuenza B viruses from the same sample. Coronaviruses are a large family of viruses that cause infections in humans and other mammals (such as camels, cats, dogs, and bats). The SARS-CoV-2 virus is a new coronavirus that was identified by the World Health Organization (WHO) (1) on February 11, 2020. Inuenza is caused by three types of immunological RNA viruses (A, B and C) in the Orthomyxoviridae family. Seasonal inuenza is typically caused by three main hem- agglutinin subtypes (H1, H2, and H3) and two neuraminidase subtypes (N1 and N2). It is important that public health laboratories around the world conduct detailed surveillance to monitor the spread and impact of the pandemic H1N1 2009 virus, as well as predict future changes in virulence (4). Therefore, methods for rapid diagnosis, case detection and follow-up of this new pathogen in the human population are necessary to develop appropriate management strategies to reduce morbidity and mortality. The test works with single-stage real time reverse transcriptase polymerase chain reaction (On- eStep RT-PCR) with serum, lower respiratory tract samples (e.g. bronchoalveolar lavage, sputum, tracheal aspirate), and upper respiratory tract samples (e.g. nasopharyngeal uids, nasal swab) from individuals who demonstrate clinical criteria set for COVID-19 by WHO (2) and CDC (Center for Disease Control and Prevention) (3). This kit is an In-vitro diagnostic kit using specific primers designed for qualitative detection of genomic RNAs of SARS-CoV-2, Inuenza A and Inuenza B virus.
Content of each kit: Test card (innovative and unique system), detailed instructions for use, sterile disposable swab, reactive solution for sample treatment, illustrative manual for use and operation.
General characteristics: CE self-diagnostic certification, holographic security label with individual code for authenticity verification, non-invasive, easy to use, no prescription required, rapid results in less than 15 minutes, high precision.
Sale restrictions: Exclusive sale to pharmacies, authorized companies, pharmaceutical distribution, socio-sanitary establishments, health establishments, occupational risk prevention, public organizations and health professionals.
Restricted sale to individuals. Sale subject to the provisions of Royal Decree 588/2021, of July 20, which modifies Royal Decree 1662/2000, of September 29, on medical devices for "in vitro" diagnosis, in order to regulate the sale to the public and the advertising of covid-19 self-diagnosis products. Sale subject in relation to tax matters to the provisions of Royal Legislative Decree 35/2020, of December 22, seventh final provision. Applicable tax rate of Value Added Tax to deliveries, imports and intra-community acquisitions of certain goods and provision of services necessary to combat the effects of SARS-CoV-2 as well as for the purposes of the special regime of the equivalence surcharge .
Intended Use:
This product is authorized and intended for use by trained laboratory or healthcare professionals for in vitro diagnostic use. Point-of-care professionals administering tests are required to report all results to the appropriate public health authorities.
Note: Consult your provincial and local health care authorities for POC guidelines for rapid testing use.
5102 Diagnostic Kits Suppliers
Short on time? Let Diagnostic Kits sellers contact you.
Bacterial Vaginosis Rapid Test Kit core Chromogenic Ingredient IBX-4041
IBX-4041 Testing vessel
BV Blue active ingredient
BVBlue active ingredient
BVBlue substrates
BV Blue substrates
Chromogenic substrate IBX-4041
chromogenic substrate of sialidase enzyme
Detection reagent for bacterial vaginosis (sialidase two-step method)
Shenzhen BST Science & Technology Co., Ltd sells and exports chromogenic substrate of sialidase enzyme IBX-4041.
Specification:
Appearance: Light yellow solid powder
Purity: 95% min
Application: Two-step chromogenic substrates of neuraminidase (sialidase)
BVBLUE Test Kit Component
1)BVBLUE Developer Solution: Water and Sodium hydroxide
2) BVBLUE Testing Vessel: Water, Potassium acetate, IBX-4041 (chromogenic substrate compound).
IBX-4041 is the key ingredient of BVBLUE test kit, BVBLUE test is a rapid sialidase test for bacterial vaginosis. BVBLUE test method is currently the only test method approved by the FDA for testing Bacterial Vaginosis(BV), The BV BLUE Test contains a chromogenic substrate of sialidase enzyme, IBX-4041.
BV Blue test is a commercially available test, it detects sialidase activity, an enzyme produced by BV-associated bacteria such as Gardnerella vaginalis, Bacteroides spp., Prevotella spp., and Mobiluncus spp. In the test procedure, a vaginal fluid sample is placed in the test vessel which contains a chromogenic substrate for sialidase. After incubation, a developer solution is added, and If the sample contained a high level of sialidase, a blue or green color is seen. Samples containing no sialidase, or low levels of this enzyme, will generate a yellow color in the reaction. The BV test has high specificity and sensitivity. The BVBlue test enables rapid detection of BV in a physician's office, and can thereby provide advantages over the Amsel methods and other methods requiring extensive laboratory testing.
Advantage of BVBLUE Test Kit
Compared to other diagnostic test methods for BV such as Amsel criteria, Nugent Gram-stain scoring system, Affirm�® Microbial Identification Test, BVBLUE Test Kit has following advantage:
1, BVBLUE Test is currently the only test method approved by the FDA for testing Bacterial Vaginosis(BV).
2, BVBLUE Test just take 10 minutes to 15 minutes to get the result.
3, High purity sialidase substrate with high specificity can reduce the occurrence of false positive.
4. Comparing with the gold standard, the coincidence rate is high, the relative sensitivity is 93%, and the specificity is 95%.
5. Easy to operate, do not need equipment.
6. The specimen does not need to pretreat.
The One Step Microalbumin Test Cassette (Urine) is intended for the qualitative detection of human serum albumin (HSA) in human urine specimens, as a screening test and as an aid in the diagnosis of renal dysfunction. This assay provides only a preliminary result. Clinical expertise and professional judgment should be sought to further evaluate the result of the test.
The IgM rapid Test Cassette (Serum/Plasma) is a lateral flow chromatographic immunoassay for the qualitative detection of IgM antibodies in human serum to Rheumatoid Factor (RF) antigen. It is intended to be used as ascreening test and as an aid in the diagnosis of rheumatoid arthritis. Any reactive specimen with the RF IgM Rapid Test Cassette must be confirmed with alternative testing method(s) and clinical findings.
Monkeypox IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)
is a solid phase immunochromatographic assay for the rapid, qualitative
and differential detection of IgG and IgM antibodies to monkeypox virus
in human whole blood, serum or plasma. This test provides only a
preliminary test result.
Blood sample size: 1-2 µL; if sample applied at the center of test pad.
Sample type: Capillary, Venous, Arterial, Neonatal.
Sample dosing: Large test pad for top dosing suitable for AST options.
Compatibility: Only with AC Active meter.
Storage: +2C to 30C.
Quality control: 2 levels - 50 mg/dL and 150 mg/dL.
Strip Stability: 18 months
Novel Coronavirus (2019-nCoV) Real-time RT-PCR Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the 2019-nCoV in oropharyngeal swabs and bronchoalveolar lavage fluid collected form individuals suspected of COVID-19 by their healthcare provider.
About SARS-CoV-2
Specific antibodies will be produced within days to weeks as the immune system makes immune defense against the SARS-CoV-2 infection. Total antibody detection is an aid in the diagnosis of patients with suspected SARS-CoV-2 infection in conjunction with clinical symptoms and result of other diagnostic methods. The test result should not be used as the sole basis for diagnosis and exclusion of SARS-CoV-2 infection. Total antibody may not be detected in the first few days of infection.
SARS-CoV-2 neutralizing antibody is a protective soluble protein secreted by adaptive immunizing cells after inoculation with SARS-CoV-2 vaccine or infection with SARS-CoV-2. These antibodies can specific bind with virus RNA binding domain (RBD) to block the binding of RBD with angiotensin-converting enzyme 2 (ACE2) on human cells surface, thus prevent the virus or its genetic material into the human cell and virus infection.
Benifits of the Kit
1) Room Temperature Transportation
2) Cost-Effective Shipping
The shipping is at room temperature, with no need of cold chain shipping.
3) Highly Sensitive, Highly Specific
Highly sensitive and highly specific for 2019-nCoV, reliable identification of COVID-19.
4) Environmentally Friendly
The kit needs neither bulky packaging nor cold chain shipping.
For the detection of eye / nose / stool / rectal secretions or blood pathogens
The most convenient and rapid diagnostic tool for canine distemper / canine parvovirus
Feature
High accuracy for monoclonal antibody capture target
Good tools for antibody detection and disease diagnosis
Easiest reagent to operate the test
Quickly present the result
Low testing cost
Technical specification
Technical Parameters for Rapid Canine Distemper Ag Test Kit
Principle: colloidal gold lateral chromatography
Test samples: eye / nasal secretions or blood
Interpretation of time: 10-15 minutes
Sensitivity: 98%
Specificity: 97%
Shelf life: 24 months
Storage temperature: 4-28
Packing: 10 Test/ box
Technical Parameters for Rapid Feline Parvovirus Ag Test Kit
